NP-G2-044
Phase 3Small molecule
NP-G2-044 is one of 53 small molecule programs targeting Ovarian Cancer. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
232 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Hycamtin
MMeitheal
Phase 3
Pegylated Liposomal Doxorubicin
Merck & Co.Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Femara
NovartisPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Adriamycin
PfizerPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Afinitor
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastasis1 trial
Ovarian Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NP-G2-044. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- NNovita Pharmaceuticals, Inc.